research 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.
Search
for
Sort by
Research
480-510 / 1000+ results
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research Faculty Opinions recommendation of Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia.
Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab
Dupilumab may cause hair loss in some patients with severe atopic dermatitis.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Review of Promising Off-Label Use of Deucravacitinib
Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
research A COMPARATIVE CLINICAL STUDY OF INTRALESIONAL PLATELET-RICH PLASMA AND INTRALESIONAL CORTICOSTEROID IN MANAGING ALOPECIA AREATA : EFFICACY AND PATIENT ACCEPTIBILITY
PRP is a promising alternative for alopecia areata due to its safety and patient satisfaction.
research Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models
A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
research Severe Pustular Drug Eruptions From Amivantamab: A Case Series
Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research Pantolactams as androgen receptor antagonists for the topical suppression of sebum production
Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
research Design of Nanocrystalline Suspension of Dutasteride for Intramuscular Prolonged Delivery
The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
research Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series
Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.
research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
research The efficacy and particular side effects of therapy peginterferon alpha-2a acute hepatitis C hemodialysed patients
Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
research Dupilumab Induced Hair Regrowth in Alopecia Totalis
Dupilumab may help regrow hair in people with severe alopecia.
research AB0597 Comparative analysis of safety data of four treatment regimens in early rheumatoid arthritis patients
Methotrexate plus prednisolone had the fewest serious side effects.
research Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.
research Drug News
Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
research Leflunomide
Leflunomide is effective for rheumatoid arthritis but has significant side effects.
research Therapy for Alopecia Areata in Mice by Stimulating the Hair Cycle with Parathyroid Hormone Agonists Linked to a Collagen-Binding Domain
PTH-CBD helps reduce hair loss in mice by stimulating hair growth directly.
research Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series
Intralesional triamcinolone effectively reduces pain and inflammation in hidradenitis suppurativa flares.
research Tether-induced tenosynovitis: The importance of an intact skin barrier
An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
research Maculopapular rash upon antibiotic therapy in a patient with rheumatoid arthritis
Methotrexate caused a rare skin rash in a rheumatoid arthritis patient, which resolved after stopping the drug.
research PLA2R1 Overexpression Causes Podocyte Injury by Inhibiting the Cell Cycle: A Clinical Cross-Sectional Investigation and Cellular Study
PLA2R1 overexpression harms kidney cells by stopping their growth cycle.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research 42175 PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials
Guselkumab significantly improves psoriasis symptoms within 12 weeks.